A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Neovascular Age-Related Macular Degeneration (LUCERNE)

NCT03823300 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

658

Enrollment

INDUSTRY

Sponsor class

Conditions

Wet Macular Degeneration

Interventions

DRUG: Faricimab
DRUG: Aflibercept
PROCEDURE: Sham Procedure

Sponsor

Hoffmann-La Roche